Karl E. Griswold
Papers
2
Total Citations
28
H-Index
2
About
Karl E. Griswold is a researcher whose work sits at the intersection of immunology, protein engineering, and therapeutic development, with a particular focus on MHC II-mediated immune recognition and epitope analysis. His most recognized contributions center on the development of high-throughput biochemical assays for quantifying peptide-MHC II binding interactions — a critical capability for understanding and engineering immunogenicity in biologic therapeutics. By scaling peptide-MHC II binding assays to 384-well format, Griswold and colleagues achieved a 75% reduction in reagent costs while maintaining analytical rigor, making epitope screening significantly more accessible for both research and drug development applications. This methodological innovation addresses a key bottleneck in the rational design of deimmunized proteins and therapeutic biologics, where identifying and eliminating T cell epitopes is essential to reducing unwanted immune responses in patients. With citations accumulating across multiple publication records of this work, Griswold's contributions have resonated within the immunoengineering and protein therapeutics communities. His research represents an important bridge between fundamental immunological principles and practical tools for next-generation biologic medicine development.
Research Focus
Key Achievements
Top Papers
- 1
- 2